Pramlintide

Pramlintide is a synthetic analogue of the pancreatic hormone amylin, modified with three proline substitutions to prevent aggregation. It is FDA-approved as Symlin for use with mealtime insulin in type 1 and type 2 diabetes.

Last reviewed 2026-10-25 by the PeptideWiki editorial team. Editorial policy.

Overview

Pramlintide is a synthetic analogue of amylin, a 37-residue hormone co-secreted with insulin by pancreatic beta cells. Amylin helps regulate glucose after meals by slowing gastric emptying, suppressing glucagon and promoting satiety. Human amylin itself is unsuitable as a drug because it readily aggregates into amyloid fibrils, which are also found in the pancreas in type 2 diabetes. Pramlintide was designed by replacing three residues with proline, borrowing from the sequence of rat amylin, which does not form fibrils.

Pramlintide was developed by Amylin Pharmaceuticals and approved by the FDA in 2005 as Symlin for adults with type 1 or type 2 diabetes who use mealtime insulin. It was the first amylin-based drug and remains the reference compound for amylin pharmacology. Its development informed newer long-acting amylin analogues, such as cagrilintide, studied in obesity. Pramlintide is given by injection at mealtimes rather than once daily or weekly.

Structure

Pramlintide is a 37-residue peptide with the sequence Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH₂. It differs from human amylin by proline substitutions at positions 25, 28 and 29 (Ala25Pro, Ser28Pro, Ser29Pro). Like amylin, it has a disulfide bond between Cys2 and Cys7 and a C-terminal amide, both important for activity. The prolines disrupt the β-sheet formation that drives amyloid aggregation. The drug is supplied as the acetate salt.

Mechanism

Pramlintide is an agonist at amylin receptors, which are formed by the calcitonin receptor in complex with receptor activity-modifying proteins (RAMPs). These receptors are found in the brainstem, particularly the area postrema, and other brain regions. Activation slows gastric emptying, suppresses postprandial glucagon secretion and enhances satiety, reducing glucose excursions after meals.

Because pramlintide does not stimulate insulin secretion itself, it is used alongside insulin. Its gastric-emptying and glucagon effects complement insulin's actions, which is why it was developed for people already using mealtime insulin. Pramlintide also has some activity at calcitonin receptors.

Research

Type 1 and type 2 diabetes trials

Randomized placebo-controlled trials evaluated pramlintide as an adjunct to mealtime insulin in people with type 1 and type 2 diabetes. They reported reductions in HbA1c and postprandial glucose excursions, along with modest weight loss, compared with insulin alone. These trials supported FDA approval of Symlin in 2005. Studies also identified a risk of severe hypoglycemia when insulin doses were not adjusted, a key consideration in its labeling.

Weight and appetite

Clinical studies examined pramlintide's effects on food intake and body weight, alone and in combination with other agents such as leptin analogues, in people with obesity. These studies helped establish amylin as a target for weight management research. The development of long-acting amylin analogues for obesity, including cagrilintide, built on this work. Studies in combination with leptin analogues were exploratory and did not lead to an approved combination product.

Amylin aggregation science

The design of pramlintide is a classic example of rational modification to prevent peptide aggregation. Biophysical studies compared human amylin, rat amylin and pramlintide, showing how proline substitutions reduce fibril formation. Human amylin aggregation remains a major research area in type 2 diabetes, where islet amyloid contributes to beta cell loss. Rat amylin, which differs at several positions and does not aggregate, served as the model for these substitutions.

Other research

Pramlintide has been studied in combination with insulin in closed-loop artificial pancreas systems, where its effects on postprandial glucose may help automated insulin delivery. It has also been examined in neurological research related to amylin and amyloid-β. These areas are investigational. Evidence from these studies is mostly small and exploratory, and they do not establish benefits beyond the approved indication. Researchers should consult the primary publications for designs and outcomes.

Regulatory status

Pramlintide is FDA-approved as Symlin as an adjunct to mealtime insulin in adults with type 1 or type 2 diabetes who have not achieved desired glucose control. Labeling includes a boxed warning about the risk of severe hypoglycemia with insulin. Indications are defined by current prescribing information. For sport, check the current WADA Prohibited List.

Status changes often. See the regulatory tracker for dated updates.

Quality and identity testing

A certificate of analysis should confirm identity by mass spectrometry against the expected mass shown on this page, which assumes the oxidized (disulfide-bonded) form. The reduced form with free cysteines is about 2 Da heavier, and disulfide-linked dimers are possible. Purity should be reported by reverse-phase HPLC. Pramlintide contains multiple asparagine residues, so deamidation (+1 Da) is a main degradation route, and the C-terminal amide should be confirmed. Although prolines reduce aggregation, aggregation should still be assessed. The counter-ion, typically acetate, and net peptide content should be stated.

Open Pramlintide in the sequence analyzer to see the expected [M+H]⁺ and multiply charged ions for an MS identity check (set the N-acetyl, amide and disulfide options to match).

For a walkthrough of each section of a certificate, see how to read a COA.

Storage and stability

Store lyophilized pramlintide sealed at -20 °C or colder, protected from moisture and light, and allow vials to reach room temperature before opening. Pramlintide is more stable in mildly acidic solutions, and the approved product is formulated at acidic pH; at neutral pH, deamidation of its asparagine residues accelerates. For lab use, prepare solutions in a suitable acidic buffer where compatible, keep them refrigerated for short-term work, aliquot for longer storage, and avoid repeated freeze-thaw cycles.

Download the Pramlintide data sheet (PDF): sequence, masses, expected MS ions and handling on one printable page.

Latest research

Frequently asked questions

Related compounds

• Cagrilintide

  Cagrilintide is an investigational long-acting acylated analogue of amylin, a pancreatic hormone involved in satiety. It has been studied alone and in combination with semaglutide (CagriSema) for weight management.

• Exenatide

  Exenatide is a 39-amino-acid GLP-1 receptor agonist, a synthetic version of exendin-4 found in Gila monster saliva. It was the first GLP-1 receptor agonist approved by the FDA, as Byetta and later Bydureon, for type 2 diabetes.

• Liraglutide

  Liraglutide is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist with a fatty acid side chain. It is FDA-approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda).

• Semaglutide

  Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy).

References

1. PubMed: all indexed literature on Pramlintide
2. ClinicalTrials.gov: registered studies mentioning Pramlintide